Today's Date: March 29, 2024
Anaergia Announces Escrow Closing of Second Tranche of the Strategic Investment   •   World Class Dyslexia, Literacy, and Neuroscience Experts Gather with Educators for Two-Day Professional Learning Event   •   Anaergia Announces Delay in the Filing of Its Audited Financial Statements and Related Disclosures   •   Coachella Concerned That People Have Sex, Says AHF   •   Navigating Birth Control: Expert Advice from Dr. Bana Kashani, OB-GYN   •   AMIGOS FOR KIDS LAUNCHES "THE MISSING REVIEW"   •   Re:wild and Colossal Biosciences team up to leverage revolutionary technology to save critically endangered species on the brink   •   Committee for Children Now Offers a PreK-12 Full-Suite Solution with the Highly Anticipated Launch of Second Step® High Scho   •   Charity Navigator Launches Women's Advocacy List for Women's History Month   •   National University Receives 2024 Military Friendly® Gold Designation   •   Navigating Spring Break Sexual Health: Advice from Dr. Deb Laino Sex and Relationship Therapist and Powerful Life Coach   •   Chosgo K23: One of the Best Bluetooth Hearing Aids for Seniors   •   Midea Group releases its first-ever ESG brand story with an unexpected VIP visit highlighting its commitment to sustainability.   •   Syngenta Group reports $32.2 billion sales and $4.6 billion EBITDA in 2023   •   Fosun Management on 2023 Annual Results: Focusing on Core Industries with Established Advantages   •   101 Mobility® Eden Prairie: Leading the Way in Mobility and Accessibility Solutions   •   Walmart Connect Announced as Presenting Sponsor of the 2024 WIN Summit   •   e.l.f. Cosmetics Debuts TikTok Shop Super Brand Day   •   Naropa University Launches Pioneering Psychedelic Minor     •   Unique online yoga platform offers lifeline for menopausal women
Bookmark and Share

Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

PARSIPPANY, N.J. , February 02 /Businesswire/ - IVERIC bio, Inc. (NASDAQ: ISEE) today reported that on February 1, 2023, the Company granted equity-based awards pursuant to the Company’s 2019 Inducement Stock Incentive Plan to 16 newly-hired, non-executive employees. These inducement grants were approved by the Company’s compensation and talent strategy committee pursuant to a delegation by the Company’s board of directors and were made as a material inducement to each employee’s acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) as a component of his or her employment compensation.

The inducement grants consisted of non-statutory stock options to purchase 368,000 shares of the Company’s common stock and 40,550 restricted stock units for shares of the Company’s common stock.

The stock options have an exercise price of $23.70 per share, equal to the closing price of Iveric Bio’s common stock on February 1, 2023. The stock option grants have a ten-year term and vest over four years, with 25% of the shares underlying the options vesting on February 1, 2024 and an additional 2.0833% of the shares underlying the options vesting at the end of each successive month thereafter. A tranche of 2,650 restricted stock units vests with respect to 100% of the shares underlying the units on April 1, 2023. A tranche of 15,600 restricted stock units vests with respect to 50% of the shares underlying the units on April 1, 2023 and the remaining 50% of the shares underlying the units on July 1, 2023. A tranche of 8,800 restricted stock units vests with respect to 50% of the shares underlying the units on April 1, 2023 and the remaining 50% of the shares on October 1, 2023. A tranche of 3,000 restricted stock units vests with respect to 50% of the shares underlying the units on April 1, 2023 and the remaining 50% of the shares on January 1, 2024. A tranche of 6,000 restricted stock units vests with respect to 100% of the shares underlying the units on January 1, 2024. A tranche of 2,000 restricted stock units vests with respect to 100% of the shares underlying the units on October 1, 2023. A tranche of 2,500 restricted stock units vests with respect to 25% of the shares underlying the units on each of February 1, 2024, February 1, 2025, February 1, 2026 and February 1, 2027. The inducement grants are subject to the terms and conditions of award agreements covering the grants and the Company’s 2019 Inducement Stock Incentive Plan.

Iveric Bio

Iveric Bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatments for retinal diseases with significant unmet medical needs. The Company is committed to having a positive impact on patients’ lives by delivering high-quality, safe and effective treatments designed to address debilitating retinal diseases including earlier stages of age-related macular degeneration. For more information on the Company, please visit www.ivericbio.com.

ISEE-G


STORY TAGS: Stock Sale/Buyback, United States, North America, Science, Other Science, Biotechnology, Research, Pharmaceutical, Optical, General Health, Health, New Jersey,

Video

White House Live Stream
LIVE VIDEO EVERY SATURDAY
alsharpton Rev. Al Sharpton
9 to 11 am EST
jjackson Rev. Jesse Jackson
10 to noon CST


Video

LIVE BROADCASTS
Sounds Make the News ®
WAOK-Urban
Atlanta - WAOK-Urban
KPFA-Progressive
Berkley / San Francisco - KPFA-Progressive
WVON-Urban
Chicago - WVON-Urban
KJLH - Urban
Los Angeles - KJLH - Urban
WKDM-Mandarin Chinese
New York - WKDM-Mandarin Chinese
WADO-Spanish
New York - WADO-Spanish
WBAI - Progressive
New York - WBAI - Progressive
WOL-Urban
Washington - WOL-Urban

Listen to United Natiosns News